Skip to content

The effects and mechanisms of exercise intervention on cognitive function in people with cognitive impairment: a randomized controlled trial

The effects and mechanisms of exercise intervention on cognitive function in people with cognitive impairment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045582
Enrollment
Unknown
Registered
2021-04-19
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Aerobic group :Aerobic exercise
Resistance group :Resistance exercise
control group:health education

Sponsors

Peking University School of Nursing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with "probable AD" diagnosed by professionals based on the NIA-AA (2011) standard, with mild to moderate severity and MMSE score of 10~26; or MCI patients (MOCA= 60 years; 3. Live in the community; 4. Both patients and caregivers are willing to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with severe physical impairment: (1) Patients with severe cardiopulmonary insufficiency: such as NYHA heart function class III or IV heart failure patients; acute coronary syndrome; ventricular arrhythmia; acute myocarditis and pericarditis; or the past 6 months Stable clinical symptoms, such as fractures, deep vein thrombosis, unhealed ulcers (especially in diabetic patients), joint swelling, etc.; (2) Patients with high risk of osteoporosis (OSTA = 24 points), severe liver and kidney disease, cancer, alcohol or drug dependence; 3. Patients who have taken drugs related to dementia treatment (such as Exelen, Arrisen, Memantine, etc.) for less than 3 months and whose condition is in an unstable phase; and take other drugs that affect cognition (such as antipsychotics) every day Drugs, anticholinergic drugs).

Design outcomes

Primary

MeasureTime frame
global cognition;executive function;memory function;neuropathological hallmarks (Ab and tau);neurotrophic factors;

Secondary

MeasureTime frame
Quality of life;neuropsychiatric symptoms;

Countries

China

Contacts

Public ContactWan Qiaoqin

School of Nursing Peking university

qqwan05@163.com+86 13810690310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 19, 2026